Hu Yi-yang, Liu Ping, Liu Cheng, Liu Cheng-hai, Xu Lie-ming
Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Zhonghua Gan Zang Bing Za Zhi. 2006 Mar;14(3):174-7.
Serum fibrotic markers were investigated for diagnosing and prognosing liver fibrosis in chronic hepatitis B.
Liver biopsy data of 93 patients before and after treatment were gathered from an experiment group (Fuzhenghuayu capsule, 36 cases) and a control group (Heluoshugan capsule, 57 cases) from multiple medical centers, using randomized and double blind strategies to evaluate the effectiveness of Fuzhenghuayu capsules against liver fibrosis. The patients were divided into 2 groups according to the treatment efficacy: an effectual group and a non-effectual group. The hepatic inflammation, liver function and serum fibrotic markers of the patients of the two groups were analyzed.
We found that (1) Liver fibrosis improved with hepatic inflammation improvement. (2) After the drug treatment, the serum HA and PIIIP levels of the effectual group decreased obviously (t = 3.34, t =3.17, P < 0.01), and the decreased degree was higher than that of the non-effectual group, but there were no changes for LN and IV-C levels. (3) Alb contents increased (t = 3.24, P < 0.01) and activities of GGT and AST and PT decreased significantly in the effectual group, but there was no change in the non-effectual group.
The serum GGT and AST activities, PT, Alb, HA and PIIIP contents in the chronic hepatitis B patients are good markers for evaluating the degree of liver fibrosis and the effectiveness of the drug action, but the values of LN and IV-C in the evaluation need to be studied more.
研究血清纤维化标志物在慢性乙型肝炎肝纤维化诊断及预后评估中的作用。
从多个医学中心收集93例患者治疗前后的肝活检数据，分为实验组（扶正化瘀胶囊组，36例）和对照组（和络舒肝胶囊组，57例），采用随机双盲策略评估扶正化瘀胶囊抗肝纤维化的疗效。根据治疗效果将患者分为两组：有效组和无效组。分析两组患者的肝脏炎症、肝功能及血清纤维化标志物。
（1）肝纤维化随肝脏炎症改善而改善。（2）药物治疗后，有效组血清HA和PIIIP水平明显下降（t = 3.34，t = 3.17，P < 0.01），下降程度高于无效组，而LN和IV - C水平无变化。（3）有效组Alb含量升高（t = 3.24，P < 0.01），GGT、AST活性及PT明显下降，无效组无变化。
慢性乙型肝炎患者血清GGT、AST活性、PT、Alb、HA及PIIIP含量是评估肝纤维化程度及药物作用效果的良好指标，但LN和IV - C在评估中的价值尚需进一步研究。
